Join PharmQD!
Become a member of our interactive community. Collaborate and network with your colleagues and trusted peers. Membership is free!
Communicate and Educate
Discuss new and important issues with your colleagues. Share your insights to help improve patient counseling.
Network With Peers
Join the conversation with trusted colleagues. Link up with professionals who share your ideas and insights.
Learn and Advance
Take free CE courses and rate courses for your peers. Find and apply for the newest jobs. Stay up-to-date on pharmacy news.
Unite
Share your experience with pharmacy students and technicians.
Create an account and receive access to the personalized box below, including your profile, bookmarks, friends, posts and more!
Hello New Member!
PharmQD Award
PharmQD.com was recently recognized with a Silver award for the Best Overall Internet Site during the Thirteenth Annual Healthcare Internet Conference in Las Vegas.
You Could Win!
Enter for your chance to win a $200 American Express® Gift Card or an Apple® iPod Touch® 8GB.
Multiple Chances to Win--Enter Early to Increase Your Odds of Winning!
MyPharm Groups
New Feature Launched!
Connect with Members Who Share Your Interests
You and other PharmQD members can now form groups around any topic. It's a great way to meet new members, stay informed, and discuss common interests.
Recent Contributors
PharmPoll
PharmNews
Featured News
Rare but Serious Brain Infection Possible Using Tysabri (natalizumab) - 02.08.2010
The U.S. Food and Drug Administration (FDA) is alerting the public that the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with the use of Tysabri (natalizumab), increases with the number of Tysabri infusions received. This new safety information, based on reports of 31 confirmed cases of PML received by the FDA as of January 21, 2010, will now be included in the Tysabri drug label and patient Medication Guide (see Data Summary for additional information).More »
Featured News
Amneal Receives FDA Approval For Tramadol/APAP Tablets - 02.08.2010
Amneal Pharmaceuticals has received FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form.More »
Featured News
Estrogen-Only HRT May Increase Risk of Asthma After Menopause - 02.08.2010
Oestrogen-only hormone replacement therapy (HRT) may increase the risk of developing asthma after the menopause, suggests a large scale study published ahead of print in the journal Thorax.
The authors base their findings on 57, 664 women, who were quizzed about their use of HRT and development of asthma symptoms every two years between 1990 and 2002.More »
Featured News
Heart Patients Usng Herbal Remedies May Be at Heightened Risk of Dangerous Drug Interactions - 02.04.2010
More and more Americans are turning to herbal remedies to help manage chronic conditions or promote general health and wellness. But many of today's popular herbal supplements, including St. John's wort, gingko biloba, garlic and even grapefruit juice can pose serious risks to people who are taking medications for heart disease, according to a review article published in the February, 9, 2010, issue of the Journal of the American College of Cardiology.
The use of these products is especially concerning among elderly patients who typically have co-morbidities, take multiple medications and are already at greater risk of bleeding, according to authors.More »
Featured News
Acetaminophen Protects Kidneys After Muscle Injury - 02.04.2010
Severe muscle injuries -- such as crush injuries suffered in earthquakes, car accidents and explosions, and muscle damage from excessive exercise or statin drug interactions -- can cause life-threatening kidney damage. Treatment has been limited to intravenous fluids and dialysis, but a new study suggests that the commonly used pain reliever acetaminophen may protect the kidneys from damage.
An international research team led by investigators at Vanderbilt University Medical Center reports in the Proceedings of the National Academy of Sciences that acetaminophen prevented oxidative damage and kidney failure after muscle injury in a rat model. The findings support further investigation of the drug's effects in patients with severe muscle injuries.More »
Latest News
Electronic Health Records Need Better Monitoring - 02.04.2010
FDA Approves Xiaflex for Debilitating Hand Condition - 02.03.2010
New Class of Brain-Protecting Drugs Emerging - 02.02.2010
PharmTalk
PharmActivity
02/09/10
- 82971 Visits
- 408 New Posts
- 205 Blog Posts
- 25 Stories
![[title-raw]](http://www.pharmqd.com/files/imagecache/thumb_block/alzheimer's disease_0.jpg){kind=small}
![[title-raw]](http://www.pharmqd.com/files/imagecache/thumb_block/Pancreatitis.jpg){kind=small}
